In this study, we examined the association of KL-VSHET+ status with five different AD-related endophenotypes that serve as biomarkers for brain amyloidosis (Aβ levels measured from CSF and amyloid PET), tau pathology (CSF Tau and pTau), and inflammation (sTREM2). The gene discussed is MAPT; the disease is Alzheimer disease.